Press release

Gubra appoints Chief Operating Officer

Hørsholm, 6 April 2016

As of 1 April 2017, Helle Kirstein Erichsen has been appointed COO of Gubra. In this newly created position Helle Kirstein Erichsen will focus on optimizing processes, logistics and resource utilization across the organization as well as ensure smooth daily operations.

Since joining Gubra three years ago, Helle Kirstein Erichsen, has served in positions of increasing responsibility, most recently as VP for In Vivo Pharmacology. Prior to Gubra, Helle has been working in various Danish biotech companies for 12 years.

“It is with great pleasure that we can announce Helle’s appointment to COO. Gubra is experiencing rapid growth in customer base and number of employees, and this has led to an increased need for focus on ensuring optimal operations. I am convinced that both Gubra, our people and our partners will benefit greatly from Helle’s approach to processes and leadership”, Henrik Blou, CEO in Gubra, says.

“I am very grateful that I have been offered this exciting opportunity. Gubra has always been an extremely dynamic and effective organization with a very strong culture, and my ambition is to maintain this high level of effectiveness and ensure commitment and empowerment throughout the organization”, Helle Kirstein Erichsen says.

About Gubra
Founded in 2008, Gubra is a privately-held biotech company located in Denmark delivering scientific counselling and contract research services. Main focus is the metabolic area (obesity, diabetes, and NASH), where we specialize in in vivo pharmacology, histology, bioinformatics and related services. Gubra delivers preclinical services to our partners by combining cutting-edge technology with our accumulated experience and proven methodology. In addition to the CRO, Gubra has several early target and drug discovery programs aimed for partnering. For more information, please visit our website at

About Helle Kirstein Erichsen
Helle Kirstein Erichsen holds a Master’s of Science and a PhD in behavioral pharmacology. Helle has a strong carrier as a people manager working 12 years in Danish drug discovery biotech companies with special focus on neurology. She has been actively involved in exploring new drug targets, characterizing candidates in early discovery and pre-clinical programs and developing/validating in vivo behavioral pharmacology models. Helle is highly motivated and passionate about developing people and organizations.